Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE-CIS phase 2 study of avelumab for severe bronchial dysplasia or carcinoma in situ of the lung
MOH_2021-05-19_009984Phase 2Not yet recruiting
- Sponsor
- פרופ' ניר פלד
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in bronchopulmonary dysplasia (BPD), sponsored by פרופ' ניר פלד. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
avelumab
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on MOH_2021-05-19_009984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-19_009984.